The content on this site is intended for healthcare professionals only
Dr Jinhui Xue speaks to ecancer about the final overall survival results from the BECOME study evaluating becotarug in combination with osimertinib in patients with EGFR exon 20 insertion–positive non-small cell lung cancer previously treated with platinum-based therapy.
The combination demonstrated encouraging survival outcomes, with a median overall survival of 18 months.
Subgroup analyses revealed differences based on insertion location, with patients harbouring far-loop insertions experiencing improved survival compared to other subtypes.
Additionally, baseline circulating tumour DNA status was associated with outcomes, with ctDNA-negative patients showing longer progression-free and overall survival.
These findings provide important insights into patient selection and the biology underlying response, supporting further development of this combination in this difficult-to-treat population.
SHR-A2009 plus EGFR tyrosine kinase inhibitor shows promising activity in EGFR-mutant lung cancer
T-cell engagers in lung cancer: Strategies to prevent and manage toxicities
ATR inhibitor plus durvalumab does not improve survival over docetaxel in advanced NSCLC
Gotistobart improves survival and response over docetaxel in previously treated squamous lung cancer
Immunoprevention and early detection of lung cancer in Africa: The LUNG-GUARD Platform
Tarlatamab improves survival over chemo in 2L SCLC regardless of prior immunotherapy or chemo
Zongertinib shows high response rates in first-line HER2-mutant advanced NSCLC
Osimertinib plus chemo improves survival across high-risk subgroups in EGFR-mutated aNSCLC
Perioperative durvalumab in addition to neoadjuvant chemotherapy shows positive results in patients with stage IIIa(N2) NSCLC
